{
    "clinical_study": {
        "@rank": "30224", 
        "arm_group": [
            {
                "arm_group_label": "High Intensity Counseling + Long Acting NRT + PRN NRT", 
                "arm_group_type": "Experimental", 
                "description": "High Intensity Counseling + Long Acting NRT + PRN NRT"
            }, 
            {
                "arm_group_label": "High Intensity Counseling + bupropion + PRN NRT", 
                "arm_group_type": "Experimental", 
                "description": "High Intensity Counseling + bupropion + PRN NRT"
            }, 
            {
                "arm_group_label": "High Intensity Counseling + varenicline + PRN NRT", 
                "arm_group_type": "Experimental", 
                "description": "High Intensity Counseling + varenicline + PRN NRT"
            }, 
            {
                "arm_group_label": "High Intensity Counseling + Long Acting NRT", 
                "arm_group_type": "Experimental", 
                "description": "High Intensity Counseling + Long Acting NRT"
            }, 
            {
                "arm_group_label": "High Intensity Counseling + bupropion", 
                "arm_group_type": "Experimental", 
                "description": "High Intensity Counseling + bupropion"
            }, 
            {
                "arm_group_label": "High Intensity Counseling + varenicline", 
                "arm_group_type": "Experimental", 
                "description": "High Intensity Counseling + varenicline"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + Long Acting NRT + PRN NRT", 
                "arm_group_type": "Experimental", 
                "description": "Low Intensity Counseling + Long Acting NRT + PRN NRT"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + bupropion + PRN NRT", 
                "arm_group_type": "Experimental", 
                "description": "Low Intensity Counseling + bupropion + PRN NRT"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + varenicline + PRN NRT", 
                "arm_group_type": "Experimental", 
                "description": "Low Intensity Counseling + varenicline + PRN NRT"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + Long Acting NRT", 
                "arm_group_type": "Experimental", 
                "description": "Low Intensity Counseling + Long Acting NRT"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + bupropion", 
                "arm_group_type": "Experimental", 
                "description": "Low Intensity Counseling + bupropion"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + varenicline", 
                "arm_group_type": "Experimental", 
                "description": "Low Intensity Counseling + varenicline"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to find an optimal smoking cessation strategy in patients\n      undergoing therapy for lung and head and neck cancers at selected cancer centers in Kentucky\n      by delivering high quality smoking cessation to all enrolled patients.  This study will also\n      examine the feasibility of routinely implementing an array of smoking cessation strategies\n      for this patient population."
        }, 
        "brief_title": "Smoking Cessation Strategies in Community Cancer Programs for Lung and Head and Neck Cancer Patients", 
        "completion_date": {
            "#text": "February 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lung Cancer", 
            "Head and Neck Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Lung Neoplasms", 
                "Smoking"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects enrolled in the study will be placed in one of twelve treatment arms.  Subjects in\n      each of the twelve treatment regimens will receive either varenicline or bupropion or\n      long-acting nicotine replacement therapy, with or without use of supplemental nicotine\n      replacement therapy, and in combination with either standard of care smoking cessation\n      counseling or high intensity/motivational smoking cessation counseling."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must be \u2265 18 years of age.\n\n          -  Patient with newly diagnosed or recurrent, histologic diagnosis of Lung cancer or\n             Head & Neck cancer (categories: Oral Cavity, Pharynx and Larynx only).\n\n          -  Having smoked at least 1 cigarette within 4 weeks of study enrollment.\n\n          -  Having at least a 10-pack year history of cigarette smoking.\n\n          -  Having smoked at least one cigarette within 1 month of cancer diagnosis.\n\n          -  Life expectancy is greater than 1 year.\n\n          -  Patient has an AUDIT score of < 10.\n\n          -  Therapy planned is of curative intent.\n\n          -  Patients must have the ability to understand and the willingness to provide signed\n             written informed consent document.\n\n        Exclusion Criteria:\n\n          -  Known allergy attributed to bupropion, varenicline, transdermal or lozenge nicotine.\n\n          -  History of suicide attempt or preparation for attempt within the past 10 years.\n\n          -  C-SRSS Baseline/Screening: Patient response of \"Yes\" to any question except question\n             1.\n\n          -  Hospitalized for psychiatric illness within the past two years.\n\n          -  History of Bipolar disorder.\n\n          -  Currently taking Bupropion for depression.\n\n          -  Patient has taken monoamine oxidase inhibitors (MAOI) in the past two weeks.\n\n          -  History of eating disorder such as anorexia or bulimia.\n\n          -  Active widespread skin disorders such as psoriasis, chronic urticarial or dermatitis\n\n          -  History of epilepsy or seizure disorder.\n\n          -  Active severe kidney or liver disease.\n\n          -  Women must not be pregnant or lactating. Women of reproductive-potential must have\n             negative serum or urine pregnancy test within 7 days prior to study enrollment and\n             agree to use method of contraception during and for 30 days following last cessation\n             drug dose.\n\n          -  Patients within three months of a myocardial infarction.\n\n          -  Patients with unstable angina or serious arrhythmia.\n\n          -  Patients with psychiatric disability judged by the investigator to be clinically\n             significant so as to preclude informed consent or compliance with drug intake.\n\n          -  Patient taking varenicline or bupropion within one month of study enrollment.\n\n          -  Participation in any other investigational drug study within 4 weeks of study\n             enrollment.\n\n          -  Currently enrolled in other professional tobacco cessation therapeutic intervention.\n\n          -  Enrollment in a concurrent cancer therapeutic trial will require prior review and\n             approval by the study site PI to determine that there are no drug interactions\n             concerns."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048917", 
            "org_study_id": "KCTN-1301"
        }, 
        "intervention": [
            {
                "arm_group_label": "High Intensity Counseling + Long Acting NRT + PRN NRT", 
                "description": "High Intensity Counseling + Long Acting NRT + PRN NRT", 
                "intervention_name": "High Intensity Counseling + Long Acting NRT + PRN NRT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High Intensity Counseling + bupropion + PRN NRT", 
                "description": "High Intensity Counseling + bupropion + PRN NRT", 
                "intervention_name": "High Intensity Counseling + bupropion + PRN NRT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High Intensity Counseling + varenicline + PRN NRT", 
                "description": "High Intensity Counseling + varenicline + PRN NRT", 
                "intervention_name": "High Intensity Counseling + varenicline + PRN NRT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High Intensity Counseling + Long Acting NRT", 
                "description": "High Intensity Counseling + Long Acting NRT", 
                "intervention_name": "High Intensity Counseling + Long Acting NRT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High Intensity Counseling + bupropion", 
                "description": "High Intensity Counseling + bupropion", 
                "intervention_name": "High Intensity Counseling + bupropion", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High Intensity Counseling + varenicline", 
                "description": "High Intensity Counseling + varenicline", 
                "intervention_name": "High Intensity Counseling + varenicline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + Long Acting NRT + PRN NRT", 
                "description": "Low Intensity Counseling + Long Acting NRT + PRN NRT", 
                "intervention_name": "Low Intensity Counseling + Long Acting NRT + PRN NRT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + bupropion + PRN NRT", 
                "description": "Low Intensity Counseling + bupropion + PRN NRT", 
                "intervention_name": "Low Intensity Counseling + bupropion + PRN NRT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + varenicline + PRN NRT", 
                "description": "Low Intensity Counseling + varenicline + PRN NRT", 
                "intervention_name": "Low Intensity Counseling + varenicline + PRN NRT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + Long Acting NRT", 
                "description": "Low Intensity Counseling + Long Acting NRT", 
                "intervention_name": "Low Intensity Counseling + Long Acting NRT", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + bupropion", 
                "description": "Low Intensity Counseling + bupropion", 
                "intervention_name": "Low Intensity Counseling + bupropion", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Low Intensity Counseling + varenicline", 
                "description": "Low Intensity Counseling + varenicline", 
                "intervention_name": "Low Intensity Counseling + varenicline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bupropion", 
                "Varenicline"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Smoking", 
            "Cessation", 
            "Bupropion", 
            "Varenicline", 
            "Nicotine", 
            "Counseling", 
            "Tobacco"
        ], 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lexington", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40536"
                }, 
                "name": "University Of Kentucky, Markey Cancer Center"
            }, 
            "investigator": {
                "last_name": "Joseph Valentino, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "12", 
        "official_title": "Optimization of Smoking Cessation Strategies in Community Cancer Programs for Newly Diagnosed Lung and Head and Neck Cancer Patients", 
        "overall_contact": {
            "email": "kyclinicaltrialsnetwork@uky.edu", 
            "last_name": "Kris Damron", 
            "phone": "859-323-1109"
        }, 
        "overall_contact_backup": {
            "email": "jvale00@email.uky.edu", 
            "last_name": "Joseph Valentino, M.D.", 
            "phone": "859-257-5097"
        }, 
        "overall_official": {
            "affiliation": "University of Kentucky", 
            "last_name": "Joseph Valentino, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Seven day point prevalence of cigarette use confirmed with CO testing at eight weeks.", 
            "measure": "Cigarette use", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048917"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Kentucky", 
            "investigator_full_name": "Joseph Valentino", 
            "investigator_title": "Study Chair", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Kentucky", 
        "sponsors": {
            "collaborator": {
                "agency": "Kentucky Lung Cancer Research Program", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Kentucky", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}